None
Quote | Enanta Pharmaceuticals Inc. (NASDAQ:ENTA)
Last: | $17.46 |
---|---|
Change Percent: | -1.09% |
Open: | $16.71 |
Close: | $17.46 |
High: | $17.76 |
Low: | $16.5 |
Volume: | 304,569 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
News | Enanta Pharmaceuticals Inc. (NASDAQ:ENTA)
2024-03-22 05:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-18 17:45:43 ET More on Inventiva Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause Inventiva resumes Phase 3 study for NASH drug, stock up 6% Inventiva drops after adverse event in Phase 3 trial for NASH drug Seeking Alphaȁ...
Message Board Posts | Enanta Pharmaceuticals Inc. (NASDAQ:ENTA)
Subject | By | Source | When |
---|---|---|---|
Investing in biotech can be risky so you | vinmantoo | investorshub | 05/09/2023 4:25:54 PM |
Vin, its good. Stay optimistic. | Jake2234 | investorshub | 05/09/2023 12:43:10 PM |
The after hours trades means lots of pain | vinmantoo | investorshub | 05/09/2023 5:15:17 AM |
Yeah the market just tanked this thing and | Jake2234 | investorshub | 05/09/2023 1:10:04 AM |
My agenda is to speak the truth. | vinmantoo | investorshub | 05/09/2023 12:33:11 AM |
News, Short Squeeze, Breakout and More Instantly...
Enanta Pharmaceuticals Inc. Company Name:
ENTA Stock Symbol:
NASDAQ Market:
Enanta Pharmaceuticals Inc. Website:
2024-03-22 05:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product S...
Enrollment Ongoing Across Three RSV Phase 2 Studies; Anticipates Announcing Topline Data for RSVPEDs and EDP-323 Challenge Study in Q3 2024 Expanded into Immunology with New Discovery Program of Oral KIT Inhibitors for First Indication in Chronic Spontaneous Urticaria; Development Candida...